Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Molecular Therapeutics

2.77
-0.1150-3.99%
Post-market: 2.770.00000.00%19:16 EDT
Volume:612.16K
Turnover:1.68M
Market Cap:128.26M
PE:-0.93
High:2.85
Open:2.82
Low:2.67
Close:2.89
Loading ...

4D Molecular Therapeutics to Focus Pipeline on Wet AMD, Cystic Fibrosis Drug Candidates

MT Newswires Live
·
10 Jan

BRIEF-4D Molecular Therapeutics Expects Primary Endpoint 52-Week Topline Data For Both 4FRONT-1 And 4FRONT-2 In H2 2027

Reuters
·
10 Jan

BRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path

Reuters
·
10 Jan

4D Molecular Therapeutics Inc: Primary Endpoint 52-Week Topline Data for Both 4Front-1 and 4Front-2 Expected in H2 2027

THOMSON REUTERS
·
10 Jan

4D Molecular Therapeutics Inc: Cash Runway Extended Under Updated Operating Plan Expected to Fund Operations Into 2028

THOMSON REUTERS
·
10 Jan

4D Molecular Therapeutics Inc - 4D-150 Well Tolerated With No Intraocular Inflammation Observed

THOMSON REUTERS
·
10 Jan

4Dmt Announces Positive Interim Data From 4D-150 Spectra Clinical Trial in Dme and Alignment With FDA on Registrational Path

THOMSON REUTERS
·
10 Jan

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path

GlobeNewswire
·
10 Jan

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

GlobeNewswire
·
10 Jan

4D Molecular Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
18 Dec 2024

4D Molecular Therapeutics Inc : Bofa Global Research Cuts Price Objective to $46 From $79

THOMSON REUTERS
·
18 Dec 2024

4Dmt Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in Iovs

THOMSON REUTERS
·
16 Dec 2024

4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now

Insider Monkey
·
26 Nov 2024

Competitive Pressures and Market Challenges Lead to Sell Rating on 4D Molecular Therapeutics

TIPRANKS
·
21 Nov 2024

4D Molecular Therapeutics: Strong Financial Position and Strategic Clinical Advancements Support Buy Rating

TIPRANKS
·
15 Nov 2024

4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Nov 2024

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
15 Nov 2024

RBC Trims Price Target on 4D Molecular Therapeutics to $39 From $40, Keeps Outperform, Speculative Risk

MT Newswires Live
·
14 Nov 2024

Promising Pipeline Developments and Expanding Opportunities Lead to Buy Rating for 4D Molecular Therapeutics

TIPRANKS
·
14 Nov 2024

4D Molecular Therapeutics Inc : Leerink Partners Cuts Target Price to $31 From $36

THOMSON REUTERS
·
14 Nov 2024